The Fisher Wallace Stimulator® does more than support wellness - it treats serious mental health conditions. Our technology was originally cleared by the FDA in 1990, and we have invested millions of dollars since then to demonstrate safety and effectiveness in multiple patient populations - from the common patient treating stress and anxiety to severe cases involving substance use disorders.
We launched three clinical trials during the pandemic as mental health conditions skyrocketed, and in January 2022, we launched a landmark pilot program with the Seattle Police Department to improve the mental health of uniformed police officers.
Mount Sinai Beth Israel Hospital study
A study conducted at Mount Sinai Beth Israel Hospital and published in the Journal of Nervous and Mental Disease concluded that Bipolar II Depression (BD II) patients who received daily treatment with the Fisher Wallace Stimulator® experienced significant reduction in self-reported depression symptoms compared to patients using a placebo device. No serious side effects or adverse events such as hypomania were experienced by patients in the study.
A study on the safety of cranial electrical stimulation
Gad Alon, PhD, PG, Susan C. Syron, PT, and Gerald V Smith, PhD, PT
J Neuro Rehab 1998;12:65-72
We tested the safety of transcranial electrical stimulation (TCES) applied to seven children (age range 2.5 to 7.5 years) with a confirmed diagnosis of cerebral palsy (CP). No adverse systemic responses were reported. These results support the hypotehsis that TCES as used in this study is a safe procedure.
A study on the physiological and therapeutic effects of high frequency electrical pulses
Saul Liss, Bernard Liss
Integrative Physiological and Behavioral Science, April-June 1996, Vol. 31, No. 2, 88-94
Human subjects were stimulated using the LISS Cranial Stimulator (the previous name of the Fisher Wallace Stimulator). The study showed stignificant increases in levels of CSF serotonin and beta endorphin were reorded post stimulation. There were also elevations in the levels of plasma serotonin, beta endorphin, GABA and DHEA together with diinished levels of cortisol and tryptophan.
A study on the impact of cranial electrical stimulation on neurochemical production
C. Normal Shealy, MD, PhD, Roger K. Cady, MD, Diane Culver-Veehoff, RN, MSW, PhD, Richard Cox, PhD, and Saul Liss, PhD
J Neurol Orthop Med Surg (1998) 18:94-97
10 patients had cerebrospinal fluid and plasma collected before and after undergoing 20 minutes of cranial electrical stimulation (CES) with a cranial electrical stimulator. Data analysis showed that cerebrospinal fluid and plasma levels of serotonin and beta-endorphin increased significantly, and melatonin increased significantly in plasma. This hypothalamic modulation may explain the reported antidepressant effect of CES.
A study on treating patients with substance abuse dependence
David A. Deitch, PhD, Jennifer Butler, BS, Charles A. Fisher, Sidney Hargrave, MA, Norman John
This report presents findings from a retrospective chart review examining the impact of CES on the retention rates of newly abstinent substance dependent individuals in community-based residential treatment. Clients who received CES sessions during their first month in residential treatment exhibited better retention rates during the first 30 days, as well as at 60 and 90 days in treatment, compared to clients who did not receive CES. Sessions were well tolerated and clients reported improved sleep and reduced stress.